文献速递肝胆胰外科

淋巴结阴性胰腺神经内分泌肿瘤的复发风险评分

Recurrence in Patients With Lymph Node-Negative Pancreatic Neuroendocrine Tumors.
PubMed 文献 · JAMA Surg · 2026-01-01

该回顾性病例对照研究纳入770例淋巴结阴性局限性胰腺神经内分泌肿瘤患者,构建13分复合风险评分,内部AUC 0.83、外部0.95,低、中、高危组复发率分别为2.4%、9.0%、27.7%,10年无病生存率分别为96.1%、83.6%、51.3%。

要点

  • 淋巴结阴性PanNET仍有10.6%复发,中位复发时间32.4个月。
  • 男性、肿瘤≥3cm、WHO分级≥2、淋巴血管侵犯为独立预测因素。
  • 13分风险评分可分层复发与生存,指导术后监测强度。

核心结论

  • 淋巴结阴性PanNET患者中部分仍存在高复发风险,验证的风险评分可分层复发和生存风险并具生物学相关性。

研究设计与样本

  • 2000至2023年5家美国高容量中心的回顾性病例对照研究,纳入770例淋巴结阴性且至少评估8枚淋巴结的局限性PanNET患者,中位随访50.6个月。

主要发现

  • 770例中82例(10.6%)复发,中位复发时间32.4个月(IQR 16.3-82.0)。
  • 独立预测因素包括男性(OR 2.2;95%CI 1.3-3.9)、肿瘤≥3cm(OR 2.64;95%CI 1.5-4.6)、WHO分级≥2(OR 3.70;95%CI 1.4-10.0)、淋巴血管侵犯(OR 3.84;95%CI 2.1-6.9)。
  • 风险评分AUC内部0.83、外部0.95;低、中、高危组复发率分别为2.4%、9.0%、27.7%(P<.001),10年DFS率分别为96.1%、83.6%、51.3%(P<.001)。
  • 复发肿瘤中肿瘤突变负荷、体细胞突变计数及CDC42BPB、DAXX、ERI2、GALNT9、MTOR、NUMA1、TRPC7基因体细胞突变较高。

关键数值与推荐

  • 风险评分基于男性、肿瘤≥3cm、WHO分级≥2、淋巴血管侵犯等独立预测因素构建,总分13分。
  • 低、中、高危组复发率分别为2.4%、9.0%、27.7%,10年DFS率分别为96.1%、83.6%、51.3%。

临床怎么用

  • 对淋巴结阴性PanNET术后患者可使用该13分风险评分进行风险分层,高危组考虑更密切的监测和风险 adapted 治疗策略。

局限性

  • 回顾性设计,样本来自5家高容量中心,外部队列基因组验证需进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lymph node (LN) metastasis is a strong predictor of tumor recurrence following pancreatectomy for localized pancreatic neuroendocrine tumors (PanNETs). However, most patients lack LN metastasis and many tumors recur. Tools to guide risk-adapted surveillance in this group are lacking. OBJECTIVE: To develop and validate a tumor recurrence and survival risk score for patients with LN-negative PanNETs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, case-control study of patients with localized PanNETs took place at 5 high-volume US institutions from 2000 to 2023. Inclusion required 8 or more evaluated LNs and negative nodal status. Median follow-up was 50.6 months. These data were analyzed from March 2025 to May 2025. EXPOSURE: Surgical resection of localized PanNETs per clinical guidelines. MAIN OUTCOMES AND MEASURES: The primary outcome was tumor recurrence. Independent predictors were identified using multivariable logistic regression and used to construct a 13-point composite risk score. Performance was assessed using C statistics. Kaplan-Meier and log-rank methods evaluated disease-free survival (DFS). Genomic profiling was conducted in an external validation cohort to identify and validate recurrence-associated mutational risk scores. RESULTS: Of 2024 patients, 770 met inclusion criteria. Median age was 58.7 (IQR, 18.4) years; 405 were male (52.6%) and 365 were female (47.4%). Most tumors were sporadic (94.1%), nonfunctional (90.4%), and located in the body/neck (50.9%). Recurrence occurred in 82 patients (10.6%) at a median of 32.4 (IQR, 16.3-82.0) months after surgery. Independent predictors included male sex (odds ratio [OR], 2.2; 95% CI, 1.3-3.9), tumor size 3 cm or larger (OR, 2.64; 95% CI, 1.5-4.6), World Health Organization grade 2 or higher (OR, 3.70; 95% CI, 1.4-10.0), and lymphovascular invasion (OR, 3.84; 95% CI, 2.1-6.9). The risk score showed strong performance (area under the receiver operating characteristic, 0.83 internally; 0.95 externally). Recurrence rates by risk group were 2.4%, 9.0%, and 27.7% (P < .001), and 10-year DFS rates of 96.1%, 83.6%, and 51.3%, for low-risk, moderate-risk, and high-risk groups, respectively (P < .001). Genomic analyses revealed higher tumor mutational burden, somatic mutation count, and somatic mutations in CDC42BPB, DAXX, ERI2, GALNT9, MTOR, NUMA1, and TRPC7 genes among recurrent tumors. CONCLUSIONS AND RELEVANCE: Despite LN-negative status, a subset of patients with PanNETs remained at high risk for recurrence. This validated risk score stratifies recurrence and survival risk showing biological relevance. These findings provide a framework for refining postoperative surveillance and risk-adapted therapeutic strategies.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Ventin M, Arya S, Zhang L, et al. Recurrence in Patients With Lymph Node-Negative Pancreatic Neuroendocrine Tumors. JAMA Surg. 2026. PMID: 41405980. doi:10.1001/jamasurg.2025.5401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。